. Loss or dysfunction of TRPV5 has been shown to severely increase urine Ca 2+ levels and the occurrence of kidney stones 3, 4 . TRPV5 belongs to the TRPV subfamily of TRP channels, which contains six members (TRPV1-TRPV6) 5 . In the TRPV subfamily, TRPV5 and TRPV6 are the only Ca 2+ -selective channels and share high sequence identity 3, 6 . In the absence of modulators, TRPV5 and TRPV6 are constitutively active channels 3 . Several endogenous modulators such as calmodulin and phosphatidylinositol 4,5-bisphosphate (PIP 2 ) have been found to stabilize these channels in the closed or open conformation, respectively 7, 8 . Additionally, the small-molecule antifungals econazole and miconazole, which are commonly used topically to treat skin infections, have been shown to effectively inhibit both TRPV5 and TRPV6 (refs. 3, 9 ). Whereas TRPV6 has a wide tissue distribution 6, 10 , TRPV5 expression is limited to the kidney 3 , where it plays a key role in Ca 2+ reabsorption in the human body 3 . No atomic structures for TRPV subfamily members were available until the recent revolution in the cryo-EM field enabled the first atomic structure determinations for TRPV1 and TRPV2 (refs. 11-13 ). Subsequently, the structures of other TRP channels have been determined using cryo-EM, revealing structural diversity among family members [14] [15] [16] [17] [18] . The X-ray structures of modified and truncated TRPV6 constructs have also been solved 19, 20 , and these structures indicated a mechanism of Ca 2+ permeation but did not provide information regarding ligand binding, modulation and channel gating. Prior to our work, the atomic structure of fulllength TRPV5 and how small molecules modulate TRPV5 at the molecular level had remained unknown.
The occurrence of kidney stones in the United States has been rising over the last decade 1 . One of the most critical risk factors is hypercalciuria, or high levels of Ca 2+ in urine 2 . Around 80% of all kidney stones are comprised primarily of Ca 2+ salts 2 . TRPV5 is a highly Ca 2+ -selective kidney-specific TRP channel that plays a major role in systemic calcium homeostasis 3 . TRPV5 is found in the apical membrane of the nephron epithelium and allows for Ca 2+ reabsorption from the urine along its concentration gradient 3 . Loss or dysfunction of TRPV5 has been shown to severely increase urine Ca 2+ levels and the occurrence of kidney stones 3, 4 . TRPV5 belongs to the TRPV subfamily of TRP channels, which contains six members (TRPV1-TRPV6) 5 . In the TRPV subfamily, TRPV5 and TRPV6 are the only Ca 2+ -selective channels and share high sequence identity 3, 6 . In the absence of modulators, TRPV5 and TRPV6 are constitutively active channels 3 . Several endogenous modulators such as calmodulin and phosphatidylinositol 4,5-bisphosphate (PIP 2 ) have been found to stabilize these channels in the closed or open conformation, respectively 7, 8 . Additionally, the small-molecule antifungals econazole and miconazole, which are commonly used topically to treat skin infections, have been shown to effectively inhibit both TRPV5 and TRPV6 (refs. 3, 9 ). Whereas TRPV6 has a wide tissue distribution 6, 10 , TRPV5 expression is limited to the kidney 3 , where it plays a key role in Ca 2+ reabsorption in the human body 3 .
No atomic structures for TRPV subfamily members were available until the recent revolution in the cryo-EM field enabled the first atomic structure determinations for TRPV1 and TRPV2 (refs. [11] [12] [13] ). Subsequently, the structures of other TRP channels have been determined using cryo-EM, revealing structural diversity among family members [14] [15] [16] [17] [18] . The X-ray structures of modified and truncated TRPV6 constructs have also been solved 19, 20 , and these structures indicated a mechanism of Ca 2+ permeation but did not provide information regarding ligand binding, modulation and channel gating. Prior to our work, the atomic structure of fulllength TRPV5 and how small molecules modulate TRPV5 at the molecular level had remained unknown.
Here, we report a cryo-EM structure of the full-length TRPV5 channel in the presence of econazole at a resolution of 4.8 Å, with the local resolution at the transmembrane (TM) region of the channel resolved to 3.5-4.0 Å. This full-length TRPV5 structure reveals that, like other TRPV subfamily members [11] [12] [13] , the channel adopts a domain-swapped architecture that is common to many voltagegated ion channels 21 . The structure depicts the inhibited state of the TRPV5 channel and allows for the identification of a putative binding site for econazole. Based on currently available structural information for TRPV channels combined with energy refinements of the econazole-bound TRPV5 structure in a membrane-mimetic environment by molecular dynamics (MD) simulations, we gained the first insight into the mechanism of TRPV5 inhibition.
(> 80%), particularly in the pore region, and was favorably expressed in our system ( Supplementary Fig. 1a ). To investigate the structure of full-length rabbit TRPV5 in the presence of econazole, we used cryo-EM, which allowed us to image TRPV5 in an aqueous environment and avoid potential artifacts of protein crystallization, such as crystal packing that may not be biologically relevant.
We determined that the econazole half-maximum inhibition (IC 50 ) was 2 μ M for rabbit TRPV5 in HEK293 cells ( Supplementary  Fig. 1b,c) , which is similar to that reported previously (IC 50 1.3 μ M) 9 . Detergent-solubilized rabbit TRPV5 was frozen in vitreous ice in the presence of 6 μ M econazole. This concentration of econazole is three to four times higher than the IC 50 values reported by our group (Supplementary Fig. 1c ) and by others in mammalian cells 9 . This was the highest concentration we could achieve while minimizing the effect of DMSO on freezing conditions and taking into account the limit of econazole solubility.
The overall resolution of the cryo-EM TRPV5 density map (TRPV5 ECN ) is 4.8 Å, with the local resolution in the TM region between 3.5 and 4 Å. This structure was reconstructed from one 3D class that contained 50,566 particles using RELION 2.0 (refs. 25, 26 ) (Table 1 , Fig. 1a and Supplementary Figs. 1d,e and 2). The number of particles that went into the final reconstruction is in line with recently published TRPV1 channel structures with various ligands 27, 28 , and we believe that the other 3D classes from this dataset represent poor-quality TRPV5 particles. The quality of the cryo-EM densities in the TM region allowed us to confidently build an atomic model of this portion of the protein ( Supplementary Figs. 2  and 3 ). The N-terminal ankyrin-repeat domain (ARD) and C terminus were resolved in the range of 4-5.5 Å, which allowed model building in this region and the fitting of a TRPV5 ARD homology model based on the TRPV6 ARD structure 29 ( Supplementary Figs. 2  and 3 ). The final TRPV5 structural model (TRPV5 ECN ) is presented in Fig. 1b. Overall TRPV5 channel architecture. All recently determined cryo-EM structures of TRP channels have revealed a domainswapped architecture that is shared by many voltage-gated ion channels [11] [12] [13] [14] [15] [16] [17] [18] . As expected, the full-length TRPV5 structure is similar to other TRPV subfamily structures [11] [12] [13] (Fig. 1a,b) . Specifically, it is a tetrameric ion channel comprised of classic TRPV channel domains, such as transmembrane helices (S1-S6), an N-terminal ARD, a linker domain, and the C-terminal TRP domain (Fig. 1b) . While our construct is a full-length TRPV5, we only were able to resolve ~85% of the total protein (Trp29-His637), owing to the N-terminal and C-terminal flexibility (Fig. 1b) . The loop region between S1 and S2 (Arg355-Ala376) is also not resolved (Fig. 1b) . The loop between S2 and S3, which is not resolved in the structures of the close homolog TRPV6 (refs. 19, 20 ), is resolved in our TRPV5 structure. This region resembles that of TRPV1 and TRPV2.
Additionally, two nonprotein densities adjacent to each TM domain of the channel were observed in our structure (Fig. 1c,d) . One was clearly visible between the S1 and S2 helices and was assigned to a tightly bound lipid molecule ( Fig. 1c and Supplementary Fig. 4a ). This density is in an analogous position to the lipid densities that have been found in previously published TRPV1 and TRPV2 structures resolved in amphipol and nanodiscs 13, 28 ( Supplementary  Fig. 4a ). TRPV5 was imaged in the presence of decyl maltose neopentyl glycol (DMNG) detergent, which suggests that this tightly bound lipid is preserved independently of the sample preparation method. On the basis of the shape of this density and the densities in published results for other TRPV channels, we assigned this density to phosphatidylcholine (Fig. 1c and Supplementary Fig. 4a ).
The second density was found positioned between S4 and S5 of each subunit and S6 of the neighboring subunit and was putatively assigned to econazole (Fig. 1d) . The TRPV1 structure with capsazepine is the only other TRPV subfamily member cryo-EM structure that was solved in the presence of an inhibitor 28 ( Supplementary  Fig. 4b) . We compared the position of the econazole density in our TRPV5 structure to that of the density assigned to capsazepine in the TRPV1 structure ( Supplementary Fig. 4b ). In both structures, these inhibitors occupy similar positions, suggesting that this ligand-binding pocket may be conserved among TRPV channels ( Supplementary Fig. 4b ).
Econazole-binding pocket. Econazole is an antifungal drug that has been shown to inhibit both TRPV5 and TRPV6 channels 9, 30 . In our experiments, rabbit TRPV5 was inhibited in the presence of 2 μM econazole when overexpressed in HEK293 cells ( Supplementary  Fig. 1b,c) . Purified TRPV5 was frozen in the presence of 6 μ M econazole, which is in the upper concentration range of the published econazole IC 50 (1.3 μ M) 9 and the IC 50 of 2 μ M determined by our group for TRPV5 expressed in the HEK293 cell line ( Supplementary  Fig. 1b,c ). An econazole molecule (either the R or S enantiomer) can be fit reasonably well into the assigned cryo-EM density by manual docking ( Supplementary Fig. 5a-c) . Although the low resolution of the structure does not allow us to unambiguously determine by cryo-EM which enantiomeric form of the drug is bound to the 
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protein, it seems that the chlorophenyl moiety of (R)-econazole fits better in the electron density ( Supplementary Fig. 5a -c). Whereas the chlorophenyl and dichlorophenyl moieties of econazole can be docked successfully into the density ( Supplementary Fig. 5a -c), the density for the imidazole ring was not resolved. However, this is probably due to the flexible nature of this moiety compared to the rest of the compound and the current resolution of the cryo-EM structure in this region. Several residues surrounding the density assigned to econazole were observed to be within interaction distance of the econazole molecule (minimum distance within 4.0 Å between heavy atoms) and, therefore, could be involved in econazole binding (Supplementary Table 1 ). However, it is of note that not all residues within interaction distance remained so during MD simulations, suggesting that some residues may play a less significant or transient role in econazole binding. Residues that stayed within 4.0 Å from at least three of the four econazole molecules during the MD simulations with either enantiomeric form (shown in boldface in Supplementary Table 1) were assigned as the putative econazolebinding pocket and include Phe425 and Ile428 located on the S3 helix, Leu460 and Cys463 located on the S4 helix, Ile486 from the S4-S5 linker region, and Ile565 located on the S6 helix of an adjacent monomer (Fig. 2a) . Although the relative contribution of these residues to the free energy of econazole binding cannot be inferred by simple energy relaxation, the MD data support the hypothesis that this mainly hydrophobic pocket may recognize and bind small molecules like econazole and miconazole that inhibit TRPV5 and TRPV6 ( Supplementary Fig. 5d,e) .
In order to provide additional evidence that this density is indeed econazole and that these residues constitute the econazole-binding pocket, we used the relatively high-throughput Xenopus oocyte two-electrode voltage clamp (TEVC) technique and tested the effect of mutating one residue on each region of the proposed putative binding pocket. Specifically, we tested the effect of Phe425Ala, Leu460Ala, Ile486Ala, and Ile565Ala mutations on TRPV5 inhibition by econazole ( Supplementary Fig. 6 ). Consistent with previous observations 30 , higher concentrations of econazole were required to achieve rabbit TRPV5 inhibition in Xenopus oocytes compared to the HEK293 expression system. In Xenopus oocytes, we used 20 µ M econazole, which resulted in ~40% inhibition of the wildtype channel (Fig. 2b,d ). Among the mutants tested, those with Phe425Ala showed a significantly reduced inhibition by econazole (Fig. 2c,d ), implicating the involvement of this residue in econazole binding. The other tested alanine mutations (Leu460Ala, Ile486Ala, and Ile565Ala) did not reduce the inhibitory effect of econazole on TRPV5 ( Supplementary Fig. 6 ). Ile486Ala and Ile565Ala were inhibited more than the wild-type TRPV5, but those mutants also displayed some inhibition by DMSO at the concentration necessary to dissolve econazole ( Supplementary Fig. 6 ), implying that processes other than econazole binding may be involved. Overall, it is likely that the Leu460, Ile486, and Ile565 residues do not contribute to econazole inhibition to the same extent as Phe425.
The econazole-binding pocket in TRPV5 resembles the 'vanilloid'-binding pocket that was identified in TRPV1 by cryo-EM 28 ( Supplementary Fig. 7 ). The TRPV1 vanilloid-binding pocket can accommodate activators (resiniferatoxin and capsaicin), as well as inhibitors, such as capsazepine, and modulators of channel activity, such as phosphatidylinositol lipids 28 ( Supplementary Fig. 7 ). It has been proposed that the exchange between phosphoinositides and the TRPV1 activators and inhibitors in this vanilloid-binding pocket allosterically regulates TRPV1 (ref. 28 ). Moreover, the vanilloid-insensitive TRPV2 channel can be transformed into the vanilloid-sensitive channel by modification of four critical residues in this vanilloid-binding pocket 31, 32 . One of these residues is located on the S3 helix: for mouse TRPV1, it is a polar Ser513, and for mouse TRPV2, it is a hydrophobic Phe467 (Fig. 2e,f) . Changing TRPV2 Phe467 to Ser467 facilitates capsaicin entering into the vanilloid-binding pocket of TRPV2 (refs. 31,32 ). Changing TRPV1 Ser513 to Tyr513, a residue that is equally as bulky as Phe467 in TRPV2, diminishes TRPV1 activation by capsaicin 31, 32 . The S3 helix of rabbit TRPV5 harbors Phe425 at the same position as mouse TRPV2 Phe467 (or rabbit TRPV2 Phe470) ( Fig. 2e ) and mouse TRPV1 Ser513 (Fig. 2f) . Intriguingly, like TRPV2, TRPV5 does not respond to capsaicin or capsazepine 9 , suggesting that the presence of the hydrophobic phenylalanine at this position may prevent these TRPV1-specific modulators from entering the TRPV5 ligandbinding pocket, but could allow for the interaction with its specific modulators via a mechanism similar to that seen for TRPV2 vanilloid insensitivity 31, 32 Additionally, our MD simulations of the econazole-bound TRPV5 tetramer also indicated high flexibility of the drug within the binding pocket of the TRPV5 subunits (r.m.s. deviations of 2.0-6.4 Å for (R)-econazole and 1.9-7.2 Å for (S)-econazole; Supplementary Fig. 8 ), whereas the TRPV5 tetramer kept its overall conformation during 25-ns MD simulation (average Cα r.m.s. deviations of the TM helices is 2.3 ± 0.1 Å for the protein bound to (R)-econazole and 1.9 ± 0.1 Å for the protein bound to (S)-econazole with respect to the initial structure derived from the electron density map; Supplementary Fig. 9a ,c). As also seen in simulations of TRPV1 bound to antagonists or agonists 33 , the four monomers in the TRPV5 tetramer show different dynamic behavior, as evident from comparison of their Cα r.m.s. fluctuations ( Supplementary  Fig. 9b,d ), in which peaks correspond to loop regions. The initial identical poses of econazole molecules (named ECN_1-ECN_4) in the four monomers of the TRPV5 tetramer (monomers A-D) differed during dynamics, with ECN_1 and ECN_2 molecules of both (R)-econazole and (S)-econazole fluctuating more than ECN_3 and ECN_4 during the production run ( Supplementary Figs. 8 and 10 ). This differential flexibility of the econazole molecules within the binding pockets may be dependent on the surrounding environment. Interestingly, the number of 1-palmitoyl-2-oleoyl phosphatidyl choline (POPC) molecules in contact with each of the three ring moieties of econazole (chlorophenyl, dichlorophenyl, and imidazole) showed moderate-to-strong correlation with the r.m.s. deviation of the most-fluctuating econazole molecules during the production run (correlation coefficients are 0.53 and 0.46 for the ECN_1 and ECN_2 (R)-molecules, respectively, and 0.7 and 0.68 for the corresponding (S)-molecules) but much lower correlation with the two econazole molecules that moved less (ECN_3 and ECN_4), suggesting a direct effect of lipid contacts on the flexibility of the econazole molecules.
TRPV5 ion-permeation pore in the presence of econazole. TRPV5 and TRPV6 are Ca 2+ -selective non-voltage-gated ion channels that belong to the TRP family of proteins 5 . The ion-permeation pore of the econazole-bound TRPV5 is comparable to that of other TRPV channels, which is formed between the S5 helix, the P-helix loop, and the S6 helix (S5-P-S6) (Fig. 3a,b) . Nevertheless, TRPV5 is a Ca 2+ -selective channel, and unique pore features are noted in the structure. Four aspartate residues (Asp542), one from each monomer, line the selectivity filter of the channel and coordinate Ca 2+ ions. In fact, a density possibly corresponding to a Ca 2+ ion along the central-pore axis was resolved in our econazole-bound TRPV5 structure (Fig. 3c) . The carboxylate groups of Asp542 are not clearly resolved in the EM map, owing to radiation damage ( Supplementary Fig. 3a) ; however, the quality of the cryo-EM densities in this region allowed backbone assignment. The position of the Asp542 side chain in the TRPV5 pore was selected based on the best-allowed rotameric position ( Supplementary Fig. 3a) .
The ionic diameter of Ca 2+ is 2.28 Å and ~10-12 Å when fully hydrated 34, 35 . The distance between the oxygen atoms of two opposing Asp542 carboxylates in the selectivity filter, as measured from and chelating Ca 2+ with 1 mM EGTA. d, Statistical summary (% inhibition) at -100 mV, ***P < 0.001, two-sample t test. Data shown are mean ± s.e.m. e,f, The econazole binding-pocket aligned to the ligand-binding pockets of TRPV2 (PDB 5AN8) (e) and TRPV1 (PDB 3J5R) (f). Residues of interest are labeled and shown as sticks.
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.3 Å at Met578, and ~4.5 Å at His582 (Fig. 3b,f) . As previously noted in the TRPV6 structure, Met577 is the key residue involved in channel closure 19, 20 (Fig. 4a ). In our current TRPV5 model, His582 is the narrowest point in the pore (Figs. 3f and 4b) . However, our 25-ns MD simulations, during which these residues moved to average minimum distances > 9 Å, did not support this assessment. Whereas both Phe574 and Met578 residues on monomers A and D maintained a 4.0 ± 0.4 and 4.1 ± 0.4 Å average minimum distance, respectively, between side chain heavy atoms of TRPV5 bound to (R)-econazole during MD simulations, the two residues on monomers B and C assumed an average minimum distance of 7.8 ± 0.4 and 7.2 ± 0.5 Å, respectively. Taken together, our data suggest that the pore of the econazole-bound TRPV5 is nonconducting, as both Phe574 and Met578 residues might obstruct Ca 2+ flow. A similar dynamic behavior was observed in the TRPV5 complex bound to (S)-econazole.
Although TRPV5 and TRPV6 share high levels of sequence homology, we noted several differences in the pore architecture between full-length rabbit TRPV5 and the mutated and truncated rat TRPV6 construct (TRPV6*) employed in its structural studies 20 ( Fig. 4a,b) . Specifically, the first residue that constricts the TRPV5 pore is Phe574, which is conserved between rabbit, rat, and human TRPV5, but diverges to Leu573 in rabbit, rat, and human TRPV6 (Fig. 4a,b) . While both side chains are hydrophobic, the observed difference in the level of pore obstruction at this amino acid position is due to the size difference between phenylalanine and leucine our model, is ~7 Å, which may require water molecules to facilitate Ca 2+ ion interaction with the filter 35 . The distance between the putative Ca 2+ ion and carboxylate oxygen atoms of the Asp542 residues in our model (Fig. 3d, dash lines) is 3.5 Å, suggesting that the density represents a partially hydrated Ca 2+ ion coordinated by the selectivity filter (Fig. 3c,d) . Moreover, the extracellular vestibule of the TRPV5 pore is predominantly electronegative (Fig. 3e) , suggesting that it directs Ca 2+ ions toward the selectivity filter. In our MD simulations, a Ca 2+ ion remains stably coordinated by the four Asp542 residues along with one (in the (R)-econazole-bound TRPV5 complex) or up to two (in the (S)-econazole-bound TRPV5) water molecules, thus maintaining a coordination number of ~7 throughout the simulation. Whereas all four oxygen atoms of the Asp542 carboxylate moieties on monomers B and C maintain an average minimum distance of 2.9 ± 0.2 Å from each other in the TRPV5 complex bound to (R)-econazole and an average distance of ~2.2 Å from the Ca 2+ ion, only two out of four oxygen atoms of the Asp542 residues on monomers A and D contribute to the Ca The lower gate of econazole-bound TRPV5 is tightly closed, as expected, owing to channel inhibition by this small molecule (Fig. 3a,b) . The inner helical bundle at the Phe574, Met578, and His582 positions constrict the pore to a diameter of ~5.9 Å at Phe574, ( Fig. 4a-c) . Another notable difference is at the position of Met578 in rabbit TRPV5 versus that of Met577 in rat TRPV6* (Fig. 4a,b) . In both channel structures, the methionine residues create a constricted region in the pore (Fig. 4a,b) , but the position of the methionine side chains are distinct for each structure (Fig. 4a,b) .
The major difference noted between the full-length rabbit TRPV5 and the rat TRPV6* structures is at the selectivity filter (Fig. 4a,b) . The side chain of Asp541 in rat TRPV6* projects toward the pore (Fig. 4a) , whereas the position of the analogous Asp542 side chain in the rabbit TRPV5 structure resembles that of voltagegated Ca 2+ channels 34,35 ( Fig. 4b-d) . The distance between the center )) (a) and TRPV5 ECN (green) b. Pore profiles were generated using HOLE. Constricting residues for each are labeled and represented as sticks. Corresponding sequence alignments of rabbit (rb), rat (r), and human (h) homologs of TRPV5 and TRPV6 are shown below. Constricting residues are in red. c, Graphic representation of the radii of the TRPV6* (blue), TRPV5 ECN (green), and CavAB (pink, PDB 4MVM) pore profiles. The dotted vertical line represents the radius of a nonhydrated calcium ion. TRPV5 ECN residues involved in pore constriction are labeled. d, Dimer ribbon representation and pore profile of CavAB generated with HOLE. Constricting residues are labeled and represented as sticks. e-g, Dimer ribbon representation of the selectivity filters for TRPV6* (blue) (e), TRPV5 ECN (green) (f) and CavAB (pink) (g). Residues expected to be involved in Ca 2+ coordination are labeled and represented as sticks. Calcium ions are shown as green spheres.
of the oxygen atoms from two opposing Asp541 in the rat TRPV6*, which coordinate Ca 2+ at the selectivity filter, is 4.6 Å, suggesting that an aspartate from each subunit binds dehydrated Ca 2+ (ref. 19 ) (Fig. 4e) . Although we could not completely resolve the side chain of Asp542 in rabbit TRPV5, our model and MD data suggest that the aspartate side chain positions in the pore could coordinate partially hydrated Ca 2+ (Fig. 4f) , as has been proposed for Ca v Ab and Ca v 1.1 channels 34-36 (Fig. 4g) .
Insight into the mechanism of econazole inhibition of TRPV5.
Econazole is a potent inhibitor of TRPV5 and TRPV6 channels, which, upon binding, critically affects ion conduction through the channel pore 9, 30 . The high level of sequence homology between these two TRPV subfamily members, as well as their comparable functional properties, has allowed us to propose a mechanism of econazole inhibition of TRPV5. The structure of TRPV6*(ref. 20 ) was solved via X-ray crystallography in the absence of any organic smallmolecule inhibitor, and the rabbit TRPV5 structure that is presented here is econazole bound. Superimposition of these two nonconducting structures revealed several conformational differences between the unbound TRPV6* (ref. 20 ) and inhibited TRPV5 structures independent of sequence conservation (Fig. 5) . Econazole binding to the hydrophobic pocket between the S3-S4 helices, the S4-S5 linker, and the S6 helix of the adjacent subunit appeared to have produced a movement of the S1-S4 helical bundle together with the S4-S5 linker away from the pore axis and to have enabled a conformational change in the loop that connects the S6 helix to the TRP domain ( Fig. 5a ). This loop movement caused constriction of the lower gate, specifically at conserved residues Phe574, Met578, and His582, thus obstructing the pore (Fig. 5b) . Moreover, this loop movement produced additional conformational changes in the TRP domain, leading to large vertical and rotational motions of the ARDs of the channel (Fig. 5c,d ). Our structural observation is consistent with a recent mutagenesis study 7 that suggested a similar gating mechanism for the TRPV5 channel and implicated His582 in this mechanism.
Intriguingly, these econazole-induced conformational changes did not significantly affect the conformation of the outer pore region of the TRPV5 channel or its selectivity filter (Fig. 5b) . This finding suggests that whereas the gating of some TRPV subfamily members involves the outer pore region, called the turret region in the case of TRPV1 (ref. 27 ) and TRPV2 (ref.
11
), TRPV5 and TRPV6 do not require large conformational changes in this region for channel gating.
Discussion
Our cryo-EM structure of the econazole-bound full-length TRPV5 channel exhibits a domain-swapped architecture, which is a hallmark of all currently determined TRP channels at atomic resolution [11] [12] [13] [14] [15] [16] [17] [18] and was recently confirmed to be present in TRPV6 (refs. 19, 20 ). Our data revealed that overall, TRPV5 and TRPV6 are similar, but the principal structural differences between them could be used to further understand the TRPV subfamily of the channels. The TRPV5 pore architecture suggests that like other Ca 2+ -selective ion channels [34] [35] [36] , it selects Ca 2+ ions through interaction with their hydration shell 35 and may not interact with Ca 2+ ions directly 19, 20 . Nevertheless, further studies will be required to better understand the mechanism of Ca 2+ ion permeation through these Ca
2+
-selective non-voltage-gated channels.
On the basis of comparisons between the TRPV5 and TRPV6 structures, we were able to make initial inferences about the mechanism of channel inhibition by econazole (Fig. 6) . First, we demonstrated that inhibitors of TRPVs interact with the channels through a conserved hydrophobic ligand-binding pocket (Fig. 6) . Next, we showed that inhibitor binding to the TRPV5 channel is associated with movements in the S1-S4 helices bundle and S4-S5 linker, which are accompanied by a conformational change in the lower gate of the channel and may lead to its closure (Fig. 6) . Finally, consistent with the recent mutagenesis and structural studies 7 , we determined that in addition to the Met578, the rotation of the Phe574 and possibly His582 into the pore may further block Ca 2+ ion flow through TRPV5 (Fig. 6) .
Here we presented a structure of the TRPV5 channel in an inhibited state. The determination of full-length TRPV5 in ligand-free and ligand-activated states will be essential to understanding the structural diversity among TRPV channel gating mechanisms and their physiological functions. This study in conjunction with future findings will potentially pave the way for novel targeted therapies for hypercalciuria and nephrolithiasis. 
Methods
Protein expression and purification. Full-length wild-type rabbit TRPV5 was expressed with a C-terminal 1D4 epitope (TETSQVAPA) in the BJ5457 S. cerevisiae strain as previously reported 11 . In order to maintain protein stability, all purification steps were conducted at 4 °C. Cells were lysed via microfluidizer (M-110Y, Microfluidics), and plasma membranes were isolated using multiple rounds of centrifugation (3,000g for 10 min, 14,000g for 35 min, 100,000g for 45 min). Plasma membranes were stored at -80 °C until needed. To purify the channel, the plasma membranes were solubilized in a buffer containing 20 mM HEPES, pH 8.0, 150 mM NaCl, 0.87 mM LMNG, 5% glycerol, 2 mM TCEP, and 1 mM PMSF for 1 h. The sample was then centrifuged at 100,000g to remove any insoluble material. The protein was then bound to an affinity-chromatography column containing 1D4 antibody conjugated CnBr-activated Sepharose 4B beads. The column was washed with a buffer containing 20 mM HEPES, pH 8.0, 150 mM NaCl, 0.064 mM DMNG, and 2 mM TCEP, and TRPV5 was eluted using buffer containing 20 mM HEPES, pH 8.0, 150 mM NaCl, 0.064 mM DMNG, 2 mM TCEP and 3 mg/mL 1D4 peptide (NH 2 -TETSQVAPA-CO 2 H). Eluted protein was concentrated and further purified by size-exclusion chromatography (Superose 6, GE Healthcare) in 20 mM HEPES, pH 8.0, 150 mM NaCl, 0.064 mM DMNG, and 2 mM TCEP. The peak fraction was centrifugally concentrated and used for subsequent cryo-EM studies. No Ca 2+ chelators were included in any of the purification buffers.
Electrophysiological recordings. Two electrode voltage clamp (TEVC) experiments in
Xenopus oocytes were performed as described previously 37 . Briefly, ovarian sacs were removed from female Xenopus laevis frogs, then oocytes were digested using 0.2 mg/mL collagenase (Sigma) in a solution containing 82.5 mM NaCl, 2 mM KCl, 1 mM MgCl 2 , and 5 mM HEPES, pH 7.4 (OR2 solution) overnight for ~16 h at 18 °C in a temperature-controlled incubator. Defolliculated oocytes were selected and kept at 18 °C in OR2 solution supplemented with 1% penicillin/streptomycin (Mediatech) and 1.8 mM CaCl 2 . cRNA was generated from the linearized rabbit TRPV5 and its mutants in the pGEMSH oocyte vector, using the mMessage mMachine kit (Ambion). 5 ng RNA was microinjected into each oocyte using a nanoliter injector system (World Precision Instruments). The experiments were performed 48-72 h after injection. TEVC measurements were performed as described previously. Briefly, oocytes were placed in a solution containing 97 mM NaCl, 2 mM KCl, 1 mM MgCl 2 , and 5 mM HEPES, pH 7.4, in which TRPV5 currents are largely blocked by Mg 2+ and trace amounts of Ca 2+ in the medium. Monovalent currents were initiated by a solution containing 96 mM LiCl, 1 mM EGTA, and 5 mM HEPES, pH 7.4. Currents were recorded with thinwall inner filament-containing glass pipettes (World Precision Instruments) filled with 3 M KCl in 1% agarose. Currents were measured with a ramp protocol from -100 mV to 100 mV applied every 500 ms, preceded by a step to -100 mV for 50 ms. Econazole was dissolved in DMSO as a stock solution at 0.4 mg/mL (0.9 mM). The stock was added directly to the aqueous buffer solutions for measurements in oocytes. To apply 20 μ M of econazole in the oocyte measurements, the final concentration of DMSO was 2.2%. Higher concentrations of DMSO inhibited wildtype TRPV5 currents, thus we could not apply higher concentrations of econazole.
Whole-cell patch clamp was performed similarly to that described for TRPV6 (ref. 37 ), with some modifications. HEK293 cells were cultured in MEM supplemented with 10% FBS and kept in a humidified incubator with 5% CO 2 at 37 °C. Cells were transfected using the Effectene reagent (Qiagen), and measurements were performed 48-72 h after transfection. Currents were measured with an Axpatch 200B amplifier using a ramp protocol from -100 mV to 100 mV applied every second. The extracellular solution contained 142 mM LiCl, 1 mM MgCl 2 , 10 mM HEPES, and 10 mM glucose, pH 7.4. Monovalent currents were initiated by the same solution containing 1 mM EGTA but no MgCl 2 . The intracellular pipette solution contained 140 mM K-gluconate, 10 mM HEPES, 5 mM EGTA, 2 mM MgCl, and 2 mM ATP, pH 7.3. For both oocytes and HEK cells, we used a LiCl-based extracellular solution, because in this solution, removal of extracellular Mg 2+ and Ca 2+ does not induce endogenous currents in nontransfected cells, unlike in Na + or K + based solutions. The econazole stock as described above was added directly to the aqueous buffer solutions for measurements in HEK cells.
Cryo-electron microscopy data collection. Filtered, concentrated TRPV5 (~2.5 mg/mL) was incubated with 5.6 μ M econazole and 3 mM fluorinated FosCholine-8, which improved particle distribution. The sample was double blotted (3.5 μ L per blot) onto 200 mesh Quantifoil 1.2/1.3 grids (Quantifoil Micro Tools); the second blot was incubated for 30 s, and the grid was plunge frozen using a Vitrobot (FEI). The grids were imaged using a 300 kV FEI Titan Krios microscope equipped with a Gatan K2 Summit direct detector camera. 50-frame movies were collected at a nominal magnification of 45 Image processing. Movies were motion corrected to compensate for beam-induced motion using MotionCor2, resulting in summed and dose-weighted micrographs 39 .
The preprocessing procedures, CTF estimation, and autopicking procedures were performed on the summed micrographs, and the 2D classification, 3D classification, and 3D autorefinement were performed with the dose-weighted micrographs. The defocus values of the motion-corrected micrographs were estimated using Gctf software 40 . All subsequent data processing was conducted in RELION 2.0 (refs. 25, 26 ). Approximately 2,000 particles were manually picked from the 3,313 micrographs and sorted into 2D classes. The best of these classes were used as templates for autopicking. A loose autopicking threshold was selected to ensure that no good particles were missed. This resulted in ~900,000 autopicked particles that were subjected to multiple rounds of 2D classification to remove false positives and suboptimal particles. The best 137,679 particles were then subjected to 3D autorefinement, followed by 3D classification into four classes. A published structure of TRPV2 low-pass filtered to 60 Å was used as an initial model for the first 3D autorefinement 11 . Subsequent classifications and refinements used the TRPV5 map from the first 3D autorefinement low-pass filtered to 60 Å as the initial model. The mask used for processing was created from the TRPV5 map from the first 3D autorefinement adjusted to a threshold of 0.005 and low-pass filtered to 15 Å. The best 3D class, containing 70,059 particles, was subjected to an additional round of 3D autorefinement and 3D reclassification. From this, the best 50,566 particles were used in the final 3D autorefinement and post-processing to yield a TRPV5 structure at an overall resolution of 4.8 Å based on the 0.143 cutoff criterion. Local resolutions were estimated using the RESMAP software 41 . TRPV5 model building. An initial homology model was generated with the I-TASSER 42 server employing all previous structures of TRPV1 (apo-TRPV1, PDB 3J5P; capsaicin-TRPV1, PDB 3J5R; RTX/DkTx-TRPV1, PDB 3J5Q), TRPV6 (apo-TRPV6, PDB 5IWK) and our previous structure of full-length TRPV2 (PDB 5HI9). This initial model was aligned to our TRPV5 cryo-EM map calculated with RELION 2.0 and was manually adjusted to fit the electron density in COOT 43 . After this initial model fitting, we refined this model against the EMderived maps using the phenix.real_space_refinement tool from the PHENIX software package 44 , employing rigid-body refinement, gradient minimization, local grid search and ADP refinement with secondary structure restraints and NCS constraints. The structures of TRPV1 (PDB 3J5P, PDB 3J5R, and PDB 3J5Q), rabbit TRPV2 (PDB 5AN8), and the new TRPV6* structure 20 (generously provided by A. I. Sobolevsky (Columbia University)) were used as references during manual building and structure adjustment and assisted in assignment of topology and improved connectivity in the model. The model was subjected to additional rounds of manual model fitting and real space refinement (RSR), resulting in a final model to map cross-correlation coefficient of 0.722.
Molecular docking and MD simulations.
Both enantiomers of econazole were manually docked to fit the assigned cryo-EM density within the four TRPV5 monomers. The atomic coordinates of the (R)-econazole-bound and (S)-econazolebound TRPV5 tetramer embedded in a 1-palmitoyl-2-oleoyl phosphatidyl choline (POPC) bilayer solvated with TIP3P water, 0.15 M NaCl, and additional neutralizing ions were used for MD simulations. Missing residues of the loop between TM helices S1 and S2 (residues 356-375) were added with MODELLER 45 using the corresponding region of the TRPV6 crystal structure (PDB 5WIP) as a template for homology modeling. A total of 50 loop models were generated, and the structure with the top discrete optimized protein energy (DOPE) 46 score was selected as an initial conformation for the loop. The starting system for MD simulations was assembled with the Membrane Builder functionality of the CHARMM-GUI webserver 47, 48 . This system (box dimension: 143 Å × 143 Å × 147 Å) consisted of the TRPV5 tetramer, (R)-or (S)-econazole molecules bound to each tetramer subunit, 450 POPC molecules, 58,725-59,185 water molecules, 213-215 sodium ions, 183-185 chloride ions, and a calcium ion in the outer pore region, totaling 276,224 atoms in the case of TRPV5 bound to (R)-econazole and 277,608 atoms for TRPV5 bound to (S)-econazole.
MD simulations were run using Gromacs 2016.3 (ref.
49
) with a time step of 2 fs for computation and CHARMM36 force field [50] [51] [52] . Initial parameters for either (R)-or (S)-econazole were obtained using the CHARMM General force field via the ParamChem webserver (https://cgenff.paramchem.org) and were further validated and optimized following published guidelines 53 . The system was first minimized using steepest descent for 5,000 steps, then 50 ps of NVT and 50 ns of NPT equilibration. The NPT equilibration was performed in 18 steps, with the first 17 steps consisting of gradually decreasing positional restraints on the heavy atoms of lipids first, then protein side chains, protein backbone and ligand ring atoms, and lastly, the remaining ligand atoms. The last step consisted of a 1 ns unrestrained NPT equilibration, which was followed by a 25-ns production run. During the equilibration, system temperature and pressure were maintained at 300 K and 1 bar, respectively, using velocity rescale 54 for temperature coupling and a ParrinelloRahman barostat for pressure coupling. Semi-isotropic pressure coupling was applied during simulation. All bonds involving hydrogen atoms were constrained using the LINCS algorithm. Short-range nonbonded interactions were cut at 12 Å. Long-range electrostatic interactions were computed using the particle mesh Ewald (PME) summation with a Fourier grid spacing of 1.6 Å. The production run was performed with the same parameters as described above but with the thermostat switched to Nose-Hoover 
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